EP3439616A1 - Crème de restauration de la barrière de lipides épidermique pour la peau du visage, le cou et la zone du décolleté pour les patients atteints de syndrome métabolique - Google Patents

Crème de restauration de la barrière de lipides épidermique pour la peau du visage, le cou et la zone du décolleté pour les patients atteints de syndrome métabolique

Info

Publication number
EP3439616A1
EP3439616A1 EP15902371.2A EP15902371A EP3439616A1 EP 3439616 A1 EP3439616 A1 EP 3439616A1 EP 15902371 A EP15902371 A EP 15902371A EP 3439616 A1 EP3439616 A1 EP 3439616A1
Authority
EP
European Patent Office
Prior art keywords
cream
skin
metabolic syndrome
patients
neck
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15902371.2A
Other languages
German (de)
English (en)
Other versions
EP3439616A4 (fr
Inventor
Julija Voicehovska
Jana JANOVSKA
Irena Daberte
Vladimirs VOICEHOVSKIS
Andrejs Skesters
Alise SILOVA
Sergejs BABIKOVS
Olga ZUBOVA
Dagmara SPRUDZA
Janis KISIS
Ludmila Ivanova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigas Stradina Universitate
Original Assignee
Rigas Stradina Universitate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigas Stradina Universitate filed Critical Rigas Stradina Universitate
Publication of EP3439616A1 publication Critical patent/EP3439616A1/fr
Publication of EP3439616A4 publication Critical patent/EP3439616A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/342—Alcohols having more than seven atoms in an unbroken chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Definitions

  • the invention relates to the field of medicine, namely family medicine (general practitioners), therapy, endocrinology, gerontology, dermatology and cosmetology and solves the problem of restoration of epidermal lipid barrier in facial skin, decollete and the neck in metabolic syndrome patients.
  • Metabolic syndrome is a combination of changes linked to disruption of metabolism, in which the lack of sensitivity to insulin develops and cell glucose uptake is diminished. Metabolic syndrome features hypertony, obesity, ischaemic heart disease, diabetes mellitus type 2. Development of metabolic syndrome includes, but not limited to increase in waist circumference (more than 102 cm in men, more than 88 cm in women); arterial blood pressure of at least 135/85 raraHg. These patiens' blood features increased lipid peroxidation markers. Oxidants activate cell responses with protein, lipid and DNA destruction.
  • Human skin represents an intricate tissue system that is based on epidermis, derma and subcutaneous fat outline. Inside basal epidermal layer melanocytes and Langerhans cells reside. Principal epidermal layer consists of fibers of protoplasm and granulous layer is comprised of cells rich in keratohyalin complexes. Derma is the connective part of the skin and makes up for the majority of volume. Derma is separated from epidermis with the basal membrane [2].
  • Water-lipid mantle forms and epidermal barrier that is made up of corneal scale-like cells which are called corncocytcs. Among them lie intercellular lipids - ceramides. Ceramides glue corneocytes together and form an impenetrable, uniform epidermal barrier.
  • Ceramid molecules posess polar structure - they feature hydrophilic heads (attract water) and lipophilic tails (attract fats).
  • Epidermal lipid barrier blocks harmful substances from entering the skin and takes part in humoral homeostasis in derma.
  • Lipid barrier consists of cholesterol, ceramides and unsaturated fatty acids (Omega-3, Omega-6). These fatty acids posess antiinflammatory properties, stimulate Langerhans cells and strengthen epidermal lipid layer [4]. Free fatty acids are located around ceramides inside the lipid layer and provide water repellency, form water-in-oil emulsion. Under the disruptive conditions, microorganisms chemicals and other exogenous, aggressive factors enter the skin through a damaged lipid layer.
  • Skin features its own system of immune cells, starring Langerhans cells (2-5% of cellular epidermis). Langerhans cells take part in destruction of bacteria and initiate immune response, under which dermal dendritic cells, epidermal macrophages and other cells take part.
  • Skin ageing is related to the state of immune system [5].
  • skin macrophage amount reduces, oxidants activate cell reactions that disrupt protein, lipid and DNA structures.
  • oxidants activate cell reactions that disrupt protein, lipid and DNA structures.
  • Such processes are most active and prominent in patients eith metabolic syndrome (MS).
  • MS eith metabolic syndrome
  • metabolic syndrome also features a latent inframmation that activates peroxidation. Accumulation of lipid peroxidation and oxidative lipoprotein and lipid layer damage lead to morphologic changes of skin structural components [6].
  • Antioxidative defense system is weakened and/or ineffective in patients with metabolic syndrome due to oxidative stress. Under such stress, keratinocyte synthesis is reduced, transepidermal water evaporation intensifies, skin becomes markedly dry with cracks and erosions present. These changes lead to microbiota imbalance, fungal skin infections and papilloma development. Restoration of epidermal lipid layer of the skin is a particularly urgent task in patients with metabolic syndrome [7].
  • Table 1 we provide the spectrum of epidermal lipid layer disorders and respective clinical features.
  • Detection of epidermal lipid barrier damage is performed via dermatoscopy (dampness/dryness, oiliness, pH) and sciasopy (dispigmentation ratio and microrelief studies). Transepidermal water loss is measured with Tewameter® TM 300 probe, Courage + Khazaka electronic GmbH, Germany. Sciascopy is performed with MoleView SIAscope V Handset, Astron, United Kingdom, and for dermatoscopy is done with HEINE alpha+, Heine Optotechnic, Germany. In testing, data on multiple characteristics is analysed and reflect the state of epidermal lipid layer [8-1 1]:
  • coriicometry skin dampness, stratum corneum water content
  • Corneometry is based on capacitance measurement in a dialectric medium. Any change of dielectric constant under water amount fluctuations in superficial skin layers leads to capacitance change. Dampness is measured on a scale, a base for which is dielectric capacitance of water - 81. Usually, skin dampness is classified in 4-6 grades (very high 45-99.0, high-normal 35.1-40.0, reduced-low 20.1-29.9, dehydrated - lower than 20.0);
  • transepidermal fluid loss - water evaporation measurement at the skin surface based on open-chamber diffusion.
  • Method is based measurement of partial water pressure in a closed chamber with a single humidity probe. An increase in partial water pressure in the chamber in a certain amount of time;
  • pH meter - pH meter is equipped with high precision glass electrode
  • mexametry evaluation of various pigments in the skin
  • Method is based on different waavelength absorption of light spectrum by the skin.
  • Mexametry is especially useful in quantitative allergy and inflammation evaluation under UV-induced damage.
  • microrelicf studies via microphotography - equipping digital tools for relief and microstructure evaluation allows for further data reevaluation and comparison through treatment.
  • compositions for treatment and prophylaxis of UV-induced skin dryness are mixtures of plants and various oils [12-14]. UV-related prooxidative influence may be corrected with vitamins- antioxidants [15-21]. Retinoids are widely used in UV-induced damage prophylaxis [22]. Local use of selenomethionine cream under sun exposure is known for skin cancer prevention [23]. Ceramides-rich moistening cream is frequently used in children with atopic dermatitis [24].
  • petroleum jelly may be used [28].
  • Petrolatum and derivatives are used after medical or cosmetic procedures that feature removal of corneal stratum (laser grinding, dermabrasion, mechanical epidermis removal, peeling).
  • a disadvantage of petrolatum is a very low absorbability, due to which it covers the skin with a greasy layer that reduces its usage, and strong occlusive effect (blocks evaporation), which leads to reduction of skin permeability and other complications.
  • Use of petrolatum is recommended only in severe damage to epidermal layer, when an overwhelming skin cell reaction is expected due to loss of external protection, and in cases when the skin itself is not able to sustain full barrier. In other cases blocking evaporation through horny layer is strongly discouraged.
  • Fatty emulsion that provides simultaneous moistening and nutrition to the skin is well researched [29]. Said emulsion does not protect from ageing that is related to free radicals induced damage of the skin in patients with metabolic syndrome.
  • the cream contains seleno-L-methionine, Vitamin E alpha- tocopherol, squalane, methyl hydroxybenzoate, glycerol monostearate 60, cetyl alcohol, middle chain triglyceride, white petrolatum, macrogol-20-glycerol monostearate, 1,2-propanediol and distilled water in the ratio of components, mass g (%):
  • cetyl alcohol 3,78 - 6,29 middle chain triglyceride 4,72 - 7,87;
  • Cream is composed as a white or yellow tinted homogenous mass with pleasant odor, according to its fatts used in composition. All cream components are permitted for use as pharmaceuticals.
  • Cream is designed for restoration of epidermal lipid barrier of facial skin, neck and decollete area in patients with metabolic syndrome.
  • Seleno-L methionine (Selenomethionine, Se-Met (SEM)— selenomethionine L-enantiomere, naturally-occurring selenium containing amino acid, notable source of selenium.
  • Selenomethionine functions as a bioantioxidant, interacts with vitamins, enzymes, biological membranes in biosystems and an organism as a whole. Interacting with glutationperoxidase, it neutralises oxides and peroxides, protects cell membranes from destruction, works as an antihistamine, stimulates collagen and keratin biosynthesis. Not only it makes skin more elastic and resilient, it also lowers seborrheic events, activates skin regeneration and restores epidermal structure.
  • Inorganic selenium selenium disulfide
  • scalp seborrhea As accepted in the US, selenium recommended daily allowance for an adult is 50-220 mkg, and in China no toxicity was noted when intake reached 750 mkg, with intoxication symptoms apearing when daily selenium intake was around 5000 mkg [38].
  • Selenomethionine is a hydrophilic substance, and its optimal amount in the cream is 0,0005-0,0015 g. With its amount lower than 0,0005 g, antioxidant action was also lowered and with amount higher than 0,0015 g it was difficult to produce the cream due to change in consistency and excessive lamination, with cream becoming less homogenous.
  • Squalane - naturally-occurring hydrocarbon of carotinoid group that resembles transparent oil with no colour or odor.
  • Squalane does not have double bonds, thus being chemically stable and may be stored for over 2 years, does not oxidize and rancidify.
  • Squalane is synthesized in sebaceous glands, is a major component of sebum and water-lipid mantle of the skin. According to demiatocosmetology, squalane is a high-grade emollient. In contrast to triglicerydes and sebum fatty acids, squalane is non-comedogenic [39-40]. On application, squalane spreads easily, forms a protective film that prevents moisture loss and enhances skin breathing.
  • Squalane Bearing natural similarity to the skin itself, squalane easily transfers through epidermis, does not leave trace of oiliness, all while giving the skin a softer and silky feel. Squalane is hydrophobic, takes active role in metabolism and bological steroid synthesis, possesses antibacterial properties and helps prevent ageing spots.
  • Optimal squalane content in the cream is 11,25 - 18,75 g. If squalane is less than 1 1 ,25 g, its smoothing and skin restoring properties were markedly reduced, and more than 18,75 g of squalane introduced difficulties in cream synthesis as decrease in compositional stability and lamination.
  • Optimal alpha-tocopherol (Vitamin E) content in the composition is 0,50 - 1,50 g.
  • Vitamin E is less than 0,5 g, its effects were markedly reduced and when it was more than 1,5 g, consistency of the cream changed, it becoming less viscous.
  • Methyl hydroxybenzoate (methyl paraben) CH3(C 6 H 4 (OH)COO - white or cream-coloured crystalline powder, poorly soluble in cold water, soluble in wark water, ethanol and propylenglycole. Possesses wide spectrum of antibacterial and antifungal properties, naturally occurs in several plants, i.e in blueberries. It is used to counter Gram-positive bacterias, molds and Gram-negative bacterias [42]. In human body, methyl parabens is absorbed easily and fully through skin or gastrointestinal tract and breaks down into simple substances and is rapidly excreted with urine without accumulation in the organism.
  • methyl paraben is used as a stabilizer and/or prolonger and effective in very low concentrations, pure form and as a 0,25%-5% alcohol solution.
  • Optimal amount of methyl paraben is noted at 0,05 - 0,15 g. When its amount was lower than 0,05 g, stabilizing effect was reduced dramatically and when it was more than 0,15 g, consistency of the cream changed with insoluble inclusions being present and visible.
  • Glycery monostearate 60 - white powder obtained from naturally occurring stearic acid and glycerol. It is a pearlescent (light reflecting), waxlike emollient, emulsifier and thickener, which was added during stabilization phase to form a homogenous emulsion.
  • Glyceryl monostearate 60 is used as a stabilizer and structuring component to prevent separation of hydrophobic and hydrophilic phases of the composition [43]. With it being less than 2,52 g, thickening effect was markedly reduces and if there was more than - 4,20 g, the composition turned excessively thick, which introduced difficulties in application.
  • Recommended amounts are 3,78 - 6,29 g. When the amount of cetyl alcohol is less than 3,78 g, emulsifying properties were reduced and cream laminated. When its amount was more than 6,29 g, composition became fluent.
  • Medium chain triglycerydes - oily fluid obtained from coconut oil, water- insoluble, can be mixed with other oils [45]. It enhances cream spreadability, dissolves lipophilic components. Recommended amounts to use are 4,72 - 7,87 g. If the composition had less than 4,72 g of medium chain triglycerides, the cream laminated markedly and in there was more than 7,87 g of said triglycerides, the cream became more fluent.
  • White petrolatum - a semi-solid hydrocarbon mixture obtained through mixing white ceresine and paraffin with fragrance oils [46].
  • Soft paraffin is used as a thickener in skin cream and ointment design. External use of petrolatum restores water-lipid protective mantle of the skin, prevents loss of fluid by the cells, reduces scaling and cracking of the skin.
  • Petrolatum is used to soften facial and hand skin, especially in environment-induced damage (sun, wind, temperature fluctuations). With its amount in the composition less than 16,05 g, its thickening effects were less pronounced and over 26,74 g cream consistency changed for markedly thicker.
  • Macrogol-20-glycerol monostearate (HO-(CH2 ⁇ CH2 ⁇ 0) perennial-H) - white powder that forms hydrogen bonds with water molecules. It is used in medicine and cosmetics as a bonding, structuring and stabilizing component that introduces smoothness to the composition [47].
  • High degree of hydrophyly allows for an effective homogenization of the composition in amount 4,40 - 7,34 g when emulsifying cream hydrophobic components. With it being less than 4,40 g, thickening effect was markedly diminished and when macrogol was more than 7,34 g, cream consistency turned excessively thick, which made the cream difficult to apply.
  • 1,2-propanediol fCH3CH(OH)CH20H) - organic substance colorless hygroscopic, odorless fluid that keeps moist, softens and disperses, and is a good solvent [48].
  • Most of low-molecular organic compounds mix with 1,2 propanedion easily, especially those containing oxygen and nitrogen. With its amounts less than 6,29 g, thickening effect was markedly reduced and when its amount was over 10,49 g cream became excessively thick.
  • Aqua - basic component of water-in-oil emulsion Recommended use is 33,0- 34,6 g. When it was less than 33,0 g, thickening effect was markedly reduced. When the amount of aqua was more than 34,6 g, cream became excessively thick, which made it difficult to use and apply.
  • Novelty cream composition was successfully used to obtain dosage forms into the tin tubes of 65,0 g and/or 30,0 g.
  • Composition of the novelty cream and production technology corresponds to standards of REGULATION (EC) No 1223/2009 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 30 November 2009 on cosmetic products, Article 11.
  • Composition includes:
  • Difficulty in manufacturing a novelty composition was in squalane, glycerol, triglycerides, petrolatum and alpha-tocopherol being hydrophobic agents and selenomethionine, macrogol and propanediol being hydrophilic agents.
  • Cream hydrophobic part manufacturing hydrophobic part of the cream was produced by melting 2,52 g of glycerol monostearate 60 and 3,78 cetyl alcohol under 65-70°C, then adding melting 16,05 g of petrolatum, then adding 11,25 g of squalane and 4,72 g of medium-chain triglycerides, then stirring until homogenous. Composition must be 60°C.
  • hydrophilic part of the cream is the following: dissolve 6,29- 10,49 g of 1,2 propanediol and 0,05-0,15 g of methyl paraben at 45-50°C in heat-resistant glassware, add remaining distilled water (aqua), stir, add 4,40-7,34 g of macrogol-20-glycerol monostearate, dissolve through heating to 60°C.
  • Cream is composed as a white or yellow tinted homogenous mass with pleasant odor, according to its fatts used in composition. Obtained cream is packed in opaque containers (tin tubes) in 65,0 and 30,0. Cream is intended for use in patients with metabolic syndrome with the aim of restoring epidermal lipid layer of facial skin, neck and decollete area. Cream possesses good component biocompatibility, is easily absorbed by the skin, cover the skin in thin elastic layer, has pH of 4,0-5,0. It also exhibits soothing effects, reduces irrtation and in prolonged use does not cause adverse reactions.
  • Clinical trial included anthropometric data (BMI, waist circumference, arterial blood pressure), blood sample tests (glucose, lipoproteins).
  • BMI waist circumference
  • blood sample tests glucose, lipoproteins.
  • MoleView SIAscope V Handset Astron, United Kingdom
  • HEINE alphas Heine Optotechnic, Germany, respectively.
  • Immunohistochemistry included CD la, CD31, CD34, CD3, CD8.
  • the cream of the new formulation has a cosmetic and medical - preventive properties, restores epidermal lipid barrier of the skin and skin barrier function in patients with the metabolic syndrome: improves turgor and hydration of the skin, restores elasticity and smooth skin relief, reduces the phenomenon of pigmentation, inflammatory papilloma.
  • Novelty cream composition represents a mixture of water and fats, fat-like and other compounds. High percentual fat and fat-like substance content is crucial in achieving epidermal bilipid layer restoration and its water-lipid mantle. Technologically it is difficult to combine such amounts of fats without the risk of lamination of end-product. For creams of this type, it is important to use specialized emulsifiers, which, when introduced in stated amounts, provide smoothness and cream-like consistency of the novelty composition. Stability under storage and good extrusion of a finished medicinal form from a container (tin tube) is crucial for patient use.
  • the stand-out feature of our composition is the use of several structure defining emulsifiers. Simultaneous use of these emulsifiers and their strictly sequential introduction in a technique described in the disclosure, provide a prominent and stable effect of complex cream composition preservation. Presence of specific hydrophilic components (aqua, selenomethionine, glycerol) and specific ratios of solvents (cetyl alcohol, glycerol), allows to retain the activity of hydrophilic (selenomethionine) and hydrophobic (tocopherol, squalane, triglicerides) active substances that form the cream.
  • hydrophilic components aqua, selenomethionine, glycerol
  • solvents cetyl alcohol, glycerol
  • Bissett DL Chatterjee R, Hannon DP. Photoprotective effect of superoxide- scavenging antioxidants against ultraviolet radiation-induced chronic skin damage in the hairless mouse. Photodermatol Photoimmunol Photomed.

Abstract

L'invention se rapporte au domaine technique de la médecine, spécifiquement à la médecine familiale (médecins généralistes), à la thérapie, à l'endocrinologie, à la gérontologie, à la dermatologie et à la cosmétologie, et résout le problème de restauration de la barrière de lipides épidermique dans la peau du visage, le décolleté et le cou chez les patients atteints de syndrome métabolique. Le but de l'invention est de développer une composition de crème qui restaure la barrière de lipides épidermique et la couche de lipides de la peau du visage, du cou et du décolleté, utilisable chez des patients atteints de syndrome métabolique. Les buts définis sont atteints par la conception d'une composition de crème ē spécifique, laquelle contient de la L-sélénométhionine, de la vitamine E, de l'alpha-tocophérol, du squalane, du 4-hydroxybenzoate de méthyle, du monostéarate de glycérol 60, de l'alcool cétylique, des triglycérides à chaînes moyennes, de la vaseline blanche, du monostéarate de macrogol-20-glycérol, du 1,2-propanediol et de l'eau distillée dans certaines relations de ratios de masses.
EP15902371.2A 2015-08-24 2015-08-25 Crème de restauration de la barrière de lipides épidermique pour la peau du visage, le cou et la zone du décolleté pour les patients atteints de syndrome métabolique Withdrawn EP3439616A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LVP-15-90A LV15082B (lv) 2015-08-24 2015-08-24 Krēms sejas ādas, kakla un dekoltē zonas epidermālās lipīdu barjeras atjaunošanai pacientiem ar metabolisko sindromu
PCT/LV2015/000006 WO2017034384A1 (fr) 2015-08-24 2015-08-25 Crème de restauration de la barrière de lipides épidermique pour la peau du visage, le cou et la zone du décolleté pour les patients atteints de syndrome métabolique

Publications (2)

Publication Number Publication Date
EP3439616A1 true EP3439616A1 (fr) 2019-02-13
EP3439616A4 EP3439616A4 (fr) 2020-03-04

Family

ID=54846286

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15902371.2A Withdrawn EP3439616A4 (fr) 2015-08-24 2015-08-25 Crème de restauration de la barrière de lipides épidermique pour la peau du visage, le cou et la zone du décolleté pour les patients atteints de syndrome métabolique

Country Status (3)

Country Link
EP (1) EP3439616A4 (fr)
LV (1) LV15082B (fr)
WO (1) WO2017034384A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6992057B2 (ja) 2016-06-10 2022-01-13 クラリティ コスメティックス インコーポレイテッド 非面皰形成性の毛髪および頭皮ケア製剤ならびにその使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0336000B1 (fr) * 1988-04-08 1993-03-17 Stada Arzneimittel Ag Crème ambiphile
US6630442B1 (en) * 1997-01-10 2003-10-07 Theodore Hersh Reparatives for chemosurgery and laser (thermal) therapy
AU6975600A (en) * 1999-09-07 2001-04-10 D.T.R. Dermal Therapy Research Inc. Topical urea composition

Also Published As

Publication number Publication date
LV15082A (lv) 2015-12-20
EP3439616A4 (fr) 2020-03-04
WO2017034384A1 (fr) 2017-03-02
LV15082B (lv) 2016-04-20

Similar Documents

Publication Publication Date Title
US11571373B2 (en) Skin care preparations for babies
BR112020002222A2 (pt) composições e métodos para melhora da flacidez da pele e do contorno corporal
TWI287995B (en) Dermatological composition containing co-enzyme Q as active ingredient
KR20190101948A (ko) 수가용화(水加溶化)된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물
AU2002317053A1 (en) Dermal therapy using phosphate derivatives of electron transfer agents
EP1420797A1 (fr) Therapie dermique mettant en oeuvre des derives de phosphate d'agents de transfert electroniques
EP1069886B1 (fr) Usage d'une formulation de produit en application locale du type emulsion huile dans l'eau, comprenant comme emulsifiant un galactolipide, pour obtenir l'effet prolonge d'une substance incorporee
CN101687106B (zh) 新型保湿剂及其用途
CA2948926A1 (fr) Preparations cosmetiques et/ou dermatologiques extemporanees
Altuntaş et al. Anti-aging potential of a cream containing herbal oils and honey: Formulation and in vivo evaluation of effectiveness using non-invasive biophysical techniques
Mehlich et al. Acidification of the skin and maintenance of the physiological skin pH value by buffered skin care products formulated around pH 4
JP2006342351A (ja) 皮膚水分含有量を調節および改善するためのスクレログルカン解重合物
EP3439616A1 (fr) Crème de restauration de la barrière de lipides épidermique pour la peau du visage, le cou et la zone du décolleté pour les patients atteints de syndrome métabolique
Lodén Moisturizers: treatment of dry skin syndrome and barrier defects
Draelos et al. The effect of vehicle formulation on acne medication tolerability
WO2020201377A1 (fr) Crème pour le traitement de la peau lésée par le soleil
JP4488933B2 (ja) シワ改善剤及び皮膚外用組成物
KR20050048287A (ko) 아토피성 피부염을 개선을 위한 화장품 조성물
JP2006248953A (ja) シワ改善剤及び皮膚外用組成物
RU2715231C1 (ru) Косметическая маска-пленка для ухода за кожей лица с витаминами в липосомах
Clarys et al. 27 New Trends in Antiaging Cosmetic Ingredients and Treatments: An Overview
KR100355953B1 (ko) 우솔릭산 및 합성팔미토일펜타펩타이드를 함유하는 화장료조성물
Faida Emulgel composition and technology substantiation for the dry skin treatment
KR20010054395A (ko) 합성 팔미토일펜타펩타이드를 함유하는 화장료조성물
JP2003055191A (ja) アトピー性皮膚炎及び各種の乾皮症、荒れ肌症用スキンケア・治療外用製剤

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180611

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

A4 Supplementary search report drawn up and despatched

Effective date: 20200131

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/107 20060101ALI20200127BHEP

Ipc: A61K 31/01 20060101ALI20200127BHEP

Ipc: A61K 8/31 20060101ALI20200127BHEP

Ipc: A61K 8/06 20060101AFI20200127BHEP

Ipc: A61Q 19/00 20060101ALI20200127BHEP

Ipc: A61P 17/00 20060101ALI20200127BHEP

Ipc: A61K 31/355 20060101ALI20200127BHEP

Ipc: A61K 8/67 20060101ALI20200127BHEP

Ipc: A61K 31/095 20060101ALI20200127BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210407